Competitive Technologies Company Profile (OTCMKTS:CTTC)

About Competitive Technologies (OTCMKTS:CTTC)

Competitive Technologies logoCalmare Therapeutics Incorporated (CTI) is a medical device company. The Company is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. The Company's medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain. The Company offers a portfolio of technologies in life, electronic, nano and physical sciences. The Company's technology portfolio includes CALMARE pain therapy treatment, neuroprotection and cognitive enhancement, sexual dysfunction therapeutic, skin pigment enhancer, wound sealant, preparation of ordered multi-layer films, silica thin films, structural steel fissure detection paint, public key encryption, growing single crystals, and video compression and moving picture experts group (MPEG)-4. The Company's subsidiary is Vector Vision, Inc.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $3.17 million
  • Outstanding Shares: 28,787,000
Average Prices:
  • 50 Day Moving Avg: $0.12
  • 200 Day Moving Avg: $0.12
  • 52 Week Range: $0.07 - $0.23
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.31 million
  • Price / Sales: 2.42
  • Book Value: ($0.44) per share
  • Price / Book: -0.25
  • EBIDTA: ($2,040,000.00)
  • Average Volume: 12,876 shs.
  • Beta: 0.05
  • Short Ratio: 3.99

Frequently Asked Questions for Competitive Technologies (OTCMKTS:CTTC)

What is Competitive Technologies' stock symbol?

Competitive Technologies trades on the OTCMKTS under the ticker symbol "CTTC."

How were Competitive Technologies' earnings last quarter?

Competitive Technologies Inc. (OTCMKTS:CTTC) announced its quarterly earnings data on Monday, November, 24th. The company reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.02. View Competitive Technologies' Earnings History.

Who are some of Competitive Technologies' key competitors?

Who are Competitive Technologies' key executives?

Competitive Technologies' management team includes the folowing people:

  • Peter F. Brennan, Independent Chairman of the Board
  • Conrad F. Mir, President, Chief Executive Officer, Director
  • Thomas P. Richtarich, Chief Financial Officer
  • Stephen J. D'Amato M.D., Chief Medical Officer
  • Carl D. O'Connell, Director
  • Rustin R. Howard, Independent Director

How do I buy Competitive Technologies stock?

Shares of Competitive Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Competitive Technologies' stock price today?

One share of Competitive Technologies stock can currently be purchased for approximately $0.11.

MarketBeat Community Rating for Competitive Technologies (OTCMKTS CTTC)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  4 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  8
MarketBeat's community ratings are surveys of what our community members think about Competitive Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Competitive Technologies (OTCMKTS:CTTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Competitive Technologies (OTCMKTS:CTTC)
No equities research coverage for this company has been tracked by


Earnings History for Competitive Technologies (OTCMKTS:CTTC)
Earnings by Quarter for Competitive Technologies (OTCMKTS:CTTC)
Earnings History by Quarter for Competitive Technologies (OTCMKTS CTTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/24/2014($0.03)($0.05)ViewN/AView Earnings Details
5/20/2014($0.03)($0.03)ViewN/AView Earnings Details
11/20/2013Q3 13($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Competitive Technologies (OTCMKTS:CTTC)

No earnings estimates for this company have been tracked by


Dividend History for Competitive Technologies (OTCMKTS:CTTC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Competitive Technologies (OTCMKTS:CTTC)
Insider Ownership Percentage: 17.50%
Institutional Ownership Percentage: 0.17%
Insider Trades by Quarter for Competitive Technologies (OTCMKTS:CTTC)
Insider Trades by Quarter for Competitive Technologies (OTCMKTS:CTTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/27/2012Richard D HornidgeDirectorBuy2,500$0.59$1,475.00View SEC Filing  
9/4/2012Stan YarbroDirectorBuy8,000$0.88$7,040.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Competitive Technologies (OTCMKTS:CTTC)
Latest Headlines for Competitive Technologies (OTCMKTS:CTTC)
DateHeadline logoCalmare Therapeutics Board of Directors Changes - February 23 at 4:34 PM logoCALMARE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi - February 23 at 4:34 PM logoCalmare Therapeutics Medical Device and Peripherals Now Listed for Sale on GSA Advantage!(R) Web Portal - January 26 at 5:45 PM logoCalmare Therapeutics Reports Third Quarter 2016 Results - January 3 at 12:42 PM logoManitok Energy Inc. Announces a New Production Milestone Exceeding 7,100 boe/d and Two Additional Well Test Results - December 8 at 8:53 AM logoAmazon Is A Must-Own Hedge Against Traditional Retail Company Headwinds - December 8 at 8:53 AM logoCALMARE THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Discl - November 21 at 4:47 PM logoCalmare Therapeutics to Present at the 5th Annual SeeThruEquity Microcap Investor Conference - May 25 at 1:00 PM logoCalmare Therapeutics Incorporated Uplists - May 23 at 9:15 AM logoCalmare Therapeutics Reports First Quarter 2016 Results - May 19 at 2:50 PM logoCalmare Therapeutics Reports Year-End 2015 Results - April 19 at 2:53 PM logoCALMARE THERAPEUTICS INC Files SEC form 10-K, Annual Report - April 14 at 5:34 PM logoCALMARE THERAPEUTICS INC Financials - March 8 at 1:04 PM logoCalmare Therapeutics Reports Third Quarter 2015 Results - March 2 at 1:00 PM logoCALMARE THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report - March 1 at 9:28 AM logoCalmare Therapeutics Awarded $15 Million General Supply Order Contract - February 18 at 12:12 PM logoCalmare Therapeutics Incorporated Appoints Christine Chansky, M.D., J.D., F.C.L.M., Chief Regulatory Officer - February 17 at 2:45 PM logoCalmare Therapeutics Discusses Complaint Settlement - February 4 at 10:24 AM logoCALMARE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers - January 15 at 5:03 PM logoCALMARE THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submiss - October 23 at 3:58 PM logoCalmare Therapeutics Incorporated to Present at the Robins Equity Research Round-up Conference - October 7 at 12:30 PM logoCALMARE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial State - September 25 at 11:36 AM logoCalmare Therapeutics G.S.A. Contract Extended Through the First Quarter of 2016 - September 16 at 1:16 PM



Competitive Technologies (CTTC) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff